

The Lancet Oncology
125 London Wall,
London EC2Y 5AS, UK
T +44 (0) 20 7424 4950
F +44 (0) 18 6585 3017

The Lancet—New York
360 Park Avenue South,
New York, NY 10010-1710, USA
T +1 212 633 3810
F +1 212 633 3853

The Lancet—Beijing
Unit 1-6, 7F, Tower W1, Oriental
Plaza, Beijing 100738, China
T +86 10 85208872
F +86 10 85189297

www.thelancet.com/oncology

Editor/Publishing Director
David Collingridge

Deputy Editor
Rob Brierley

Senior Editors
Cassandra Coburn
Allison Landman
Isabel Lokody
Alex Sklan

Managing Editors
Lucy Banham
Hannah Jones

Senior Deputy Managing Editor
Laura Pryce

Deputy Managing Editors
Olava Astudillo
Tim Dehnel

Senior Assistant Editors
Stephanie Clague
Sean Cleghorn
Katherine Gourd
Natalie Harrison
Richard Henderson
Samuel Hinsley
Patricia Lobo
Zena Nyakoojo
Helen Penny
Louise Rishton
Priya Venkatesan
Luke Worley

Assistant Editors
Nicolas Dolan
Josefine Gibson
Emilia Harding
Rhiannon Howe
Cheryl Lai
Esther Lau
Marta Lozano-Wilhelmi
Jenniffer Thorley
Francesca Towey

Web Editors
Richard Lane
Naomi Lee
Erika Niesner

Senior Assistant Web Editor
Helen Ng

North America Editor
Rebecca Cooney (New York)

Asia Editor
Helena Hui Wang (Beijing)

Conference Editor
Laura Hart

Media Relations Manager
TBD

Media Relations Assistant
Caroline Brogan

Publisher/Editorial Director
Richard Horton

Edition
Eur

Cover
For the cover inspiration,
see page e13



Paul Price

Editorial

- 1 Climate change and non-communicable diseases

Comment

- 2 ENDEAVOR to change treatment for multiple myeloma?
C Scheid
- 3 Price, value, and the cost of cancer drugs
T Fojo, A W Lo
- 5 A new standard of care for mantle cell lymphoma?
S Rule
- 6 Mature answers but new questions in indolent and mantle-cell lymphoma
M R Smith
- 8 HPV vaccines: so much learnt, so many more lessons to come
J M L Brotherton
- 9 Nintedanib and ovarian cancer: standardise surgery in trials?
S Kehoe
- 11 S-1 versus taxanes for HER2-negative metastatic breast cancer
M Martin, S Lopez-Tarruella
- 12 S-1 with leucovorin for gastric cancer: how far can it go?
T-W Liu, L-T Chen
- 14 Detection of DCIS and reduced invasive interval cancers
A Evans
- 15 Palliative sedation: more data and fewer opinions
A Caraceni
- 17 Importance of including patients with comorbidities in clinical trials
K R Spencer, J M Mehnert
- 18 Actual costs of cancer drugs in 15 European countries
W H van Harten and others

Correspondence

- e1 Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia
M A Kharfan-Dabaja and others; A Rambaldi and others
- e2 The role of a meal on gastrointestinal toxicity and maximum tolerated dose
G Yu and others
- e3 Radiation dose and checkpoint blockade immunotherapy: unanswered questions
A M Monjazeb, J D Schoenfeld
- e4 Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
R J Motzer and others

Corrections

- e6 Correction to *Lancet Oncol* 2015; **16**: 303
- e6 Correction to *Lancet Oncol* 2016; **17**: 65
- e6 Correction to *Lancet Oncol* 2016; **17**: e8

News

- 21 NICE guidance on pembrolizumab for advanced melanoma
I Watson and others
- e7 Patient risk factors versus physician guidelines for anti-emetics
V S Balakrishnan
- e7 Defining the genetics of melanoma progression
T K Burki
- e8 Genetic mutations in paediatric cancer
H Baker
- e8 Cancer survivors' risk of future admission to hospital
T K Burki
- e9 NICE restructures the Cancer Drugs Fund
T K Burki
- e9 Internal mammary node irradiation and breast cancer survival
P Venkatesan
- e10 Herbal medicines safety concerns in patients with cancer
S Bagcchi
- e10 Cervical cancer diagnosis and the US Affordable Care Act
T K Burki
- e11 Use of antidepressants and breast cancer recurrence
H Baker
- e11 Venetoclax targets BCL2 in chronic lymphocytic leukaemia
V Brower
- e12 Aggressive tobacco marketing and allegations of corruption
T K Burki
- e12 ADT in prostate cancer and risk of Alzheimer's disease
S Bagcchi

Cancer and Society

- 23 Melatonin: resetting the clock of cancer progression?
D J Pinato, J Stebbing
- 24 Consume, digest, and expire: the risks of domesticated carcinogens
P K Tang
- 25 Framing loss
A Bianchi
- 26 The war on cancer: are we winning?
J Morgan

(Continues on next page)

Peer-reviewed and fast-tracked to publication within 8 weeks

See www.thelancet.com for supplementary material

See www.thelancet.com for podcast













Version verified by CrossMark

Open Access article

For e-pages go to www.thelancet.com/oncology

(Continued from previous page)

Articles


- 27  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
M A Dimopoulos and others
- 39  Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
S Vogler and others
- 48  Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
M L Wang and others
- 57  Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
M Rummel and others
- 67   Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
R Sankaranarayanan and others
- 78  Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
A du Bois and others
- 90  Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
T Takashima and others
- 99  S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
S Hironaka and others
- 109   Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study
SW Duffy and others
- 115  Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study
I Maeda and others

Review

- e13  Barriers to access to opioid medicines: a review of national legislation and regulations of 11 central and eastern European countries
M J M Vranken and others
- e23 A new classification for mandibular defects after oncological resection
J S Brown and others

Policy Review

- e31 Postmarket policy considerations for biosimilar oncology drugs
M J Renwick and others



If you would like to respond to an article published in **The Lancet Oncology**, please submit your correspondence online at: <http://ees.elsevier.com/thelancetoncology>

International Advisory Board

Frederic Amant (Belgium)
Carlos Barrios (Brazil)
Ambros Beer (Germany)
Eduardo Cazap (Argentina)
Noreen Chan (Hong Kong)
Ian Chau (UK)
Li-Tzong Chen (Taiwan)
Lotfi Chouchane (Qatar)
Bertrand Coiffier (France)
Javier Cortes (Spain)
Felicetto Ferrara (Italy)
Alejandro Forner (Spain)
Gemma Gatta (Italy)
Mhamed Harif (Morocco)
Roy Herbst (USA)
Jeffrey Infante (USA)
James Larkin (UK)
Brigitte Ma (Hong Kong)
Jacobus Pfisterer (Germany)
Philip Philip (USA)
Tamás Pintér (Hungary)
Chantel Quinten (Sweden)
Jorge Reis-Filho (USA)
Caroline Robert (France)
Fred Saad (Canada)
David Schiff (USA)
Charles Swanton (UK)
David Thomas (Australia)
Scott Williams (Australia)
Yi-Long Wu (China)


Information for Authors

See www.thelancet.com/authors/oncology/authorinfo for guidelines for authors.

Ombudsman

Malcolm Molyneux (c/o The Lancet or ombudsman@lancet.com)

 Peer-reviewed and fast-tracked to publication within 8 weeks

 See www.thelancet.com for supplementary material

 See www.thelancet.com for podcast

 Version verified by CrossMark

 Open Access article

For e-pages go to www.thelancet.com/oncology